

# The team of Prof. Nicholls at the Linnaeus University employ their Attana Cell™ 200 instruments in their Covid-19 research

[Prof. Ian A. Nicholls at the Linnaeus University](#) has initiated a project for therapeutic against the corona virus. The team of Prof. Nicholls has access to Biosafety laboratories class 2 for infectious diseases and laboratories for human blood studies. The main technology in proof of concept testing will be their Attana Cell 200 instruments.

The project is in an early start up phase and more information will be provided later on. Attana will support the team of Prof. Nicholls with our knowledge in order to secure as fast development as possible.

**For more information, please contact:**

Teodor Aastrup, CEO Attana AB  
e-mail: [teodor.aastrup@attana.com](mailto:teodor.aastrup@attana.com)  
tel: + 46 8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.

Attana was founded in 2002 with the vision of *in-vitro* characterization of molecular interactions mimicking *in-vivo* conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana's products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana's contract research services and our label free cell-based biosensors, please visit [www.attana.com](http://www.attana.com) or contact [sales@attana.com](mailto:sales@attana.com).